依託孕烯

依託孕烯
臨床資料
商品名（英語：Drug nomenclature）	Circlet, Implanon, Nexplanon, others
其他名稱	ORG-3236; SCH-900702 (with EE); 3-Ketodesogestrel; 3-Oxodesogestrel; 11-Methylenelevonorgestrel; 11-Methylene-17α-ethynyl-18-methyl-19-nortestosterone; 11-Methylene-17α-ethynyl-18-methylestr-4-en-17β-ol-3-one
AHFS/Drugs.com	專業藥物信息
MedlinePlus	a604032
懷孕分級	澳: B3 ; ;
給藥途徑	皮下植入器（英語：Subcutaneous implant）、陰道環
藥物類別（英語：Drug class）	黃體酯酮 (藥物)（英語：Progestogen (medication)）; 黃體素
ATC碼	G03AC08 (WHO) ;
法律規範狀態
法律規範	澳：限醫生處方（S4）; 加：處方藥（℞-only）; 歐：Rx-only; 英：處方藥（℞-only） (POM); 美：處方藥（℞-only）; 處方藥（℞-only）;
藥物動力學數據
生物利用度	植入：100%; 陰道環：100%
血漿蛋白結合率	≥98%（66%與白蛋白（英語：human serum albumin），32%與性激素結合球蛋白）結合
藥物代謝	肝臟（CYP3A4）
生物半衰期	21–38小時
排泄途徑	尿（主）、糞便（少）
識別資訊
	IUPAC命名法 (8S,9S,10R,13S,14S,17R)-13-Ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one; ;
CAS號	54048-10-1
PubChem CID	21729469;
IUPHAR/BPS	7590;
DrugBank	DB00294 ;
ChemSpider	5292944 ;
UNII	304GTH6RNH;
KEGG	D04104 ;
ChEBI	CHEBI:50777 ;
ChEMBL	ChEMBL1531 ;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID9046782 ;
ECHA InfoCard	100.053.561
化學資訊
化學式	C22H28O2
摩爾質量	324.46 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES CC[C@]12CC(=C)[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34;
	InChI InChI=1S/C22H28O2/c1-4-21-13-14(3)20-17-9-7-16(23)12-15(17)6-8-18(20)19(21)10-11-22(21,24)5-2/h2,12,17-20,24H,3-4,6-11,13H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1 ; Key:GCKFUYQCUCGESZ-BPIQYHPVSA-N ;

依託孕烯（英語：Etonogestrel）是一種人工合成的甾體有機化合物，化學式C₂₂H₂₈O₂，可作為依託孕烯植入器的藥物用於女性避孕^[9]

參考文獻

^ Ryan KJ. Kistner's Gynecology and Women's Health. Mosby. 1999: 300. ISBN 978-0-323-00201-1.
^ NEXPLANON : Etonogestrel extended release subdermal implant (PDF). Pdf.hres.ca. [2022-06-08]. （原始內容存檔 (PDF)於2022-06-10）.
^ List of nationally authorised medicinal products : Active substance: etonogestrel : Procedure no.: PSUSA/00001331/202109 (PDF). Ema.europa.eu. [2022-06-08]. （原始內容存檔 (PDF)於2022-06-10）.
^ ^4.0 ^4.1 ^4.2 ^4.3 ^4.4 Nexplanon- etonogestrel implant. DailyMed. 18 November 2019 [25 September 2020]. （原始內容存檔於10 June 2022）.
^ ^5.0 ^5.1 ^5.2 ^5.3 NuvaRing- etonogestrel and ethinyl estradiol insert, extended release. DailyMed. 24 January 2020 [25 September 2020]. （原始內容存檔於8 August 2020）.
^ Runnebaum BC, Rabe T, Kiesel L. Female Contraception: Update and Trends. Springer Science & Business Media. 6 December 2012: 156–163. ISBN 978-3-642-73790-9.
^ Holtsclaw JA. Progress Towards the Total Synthesis of Desogestrel and the Development of a New Chiral Dihydroimidazol-2-ylidene Ligand. University of Michigan. 2007: 25. In 1981, desogestrel was marketed as a new low dose oral contraceptive under the trade names Marvelon and Desogen.32
^ Mosby's GenRx: A Comprehensive Reference for Generic and Brand Prescription Drugs. Mosby. 2001: 687. ISBN 978-0-323-00629-3. The elimination half-life for 3-keto-desogestrel is approximately 38 ± 20 hours at steady state.
^ Borsch, Julia. [www.deutsche-apotheker-zeitung.de/news/artikel/2017/08/14/verhuetungsringe-jetzt-auch-ungekuehlt Verhütungsringe jetzt auch ungekühlt] 請檢查|url=值 (幫助). DAZ.online. 2017-08-14.

外部連結

[Ryan1999-1] Ryan KJ. Kistner's Gynecology and Women's Health. Mosby. 1999: 300. ISBN 978-0-323-00201-1.

[2] NEXPLANON : Etonogestrel extended release subdermal implant (PDF). Pdf.hres.ca. [2022-06-08]. （原始內容存檔 (PDF)於2022-06-10）.

[3] List of nationally authorised medicinal products : Active substance: etonogestrel : Procedure no.: PSUSA/00001331/202109 (PDF). Ema.europa.eu. [2022-06-08]. （原始內容存檔 (PDF)於2022-06-10）.

[NexplanonLabel-4] 4.0 ^4.1 ^4.2 ^4.3 ^4.4 Nexplanon- etonogestrel implant. DailyMed. 18 November 2019 [25 September 2020]. （原始內容存檔於10 June 2022）.

[NuvaRingLabel-5] 5.0 ^5.1 ^5.2 ^5.3 NuvaRing- etonogestrel and ethinyl estradiol insert, extended release. DailyMed. 24 January 2020 [25 September 2020]. （原始內容存檔於8 August 2020）.

[RunnebaumRabe2012-6] Runnebaum BC, Rabe T, Kiesel L. Female Contraception: Update and Trends. Springer Science & Business Media. 6 December 2012: 156–163. ISBN 978-3-642-73790-9.

[Holtsclaw2007-7] Holtsclaw JA. Progress Towards the Total Synthesis of Desogestrel and the Development of a New Chiral Dihydroimidazol-2-ylidene Ligand. University of Michigan. 2007: 25. In 1981, desogestrel was marketed as a new low dose oral contraceptive under the trade names Marvelon and Desogen.32

[Mosby2001-8] Mosby's GenRx: A Comprehensive Reference for Generic and Brand Prescription Drugs. Mosby. 2001: 687. ISBN 978-0-323-00629-3. The elimination half-life for 3-keto-desogestrel is approximately 38 ± 20 hours at steady state.

[9] Borsch, Julia. [www.deutsche-apotheker-zeitung.de/news/artikel/2017/08/14/verhuetungsringe-jetzt-auch-ungekuehlt Verhütungsringe jetzt auch ungekühlt] 請檢查|url=值 (幫助). DAZ.online. 2017-08-14.

[9]

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]